

Applicants : KING, et al.  
U.S. Serial No. : Not Yet Known  
Filing Date : Herewith  
Page : 7

REMARKS

Applicants have hereinabove canceled claims 13 and 22-33 without prejudice to Applicants' right to pursue these matters in a future application. Applicants further amend claims 3-5, 10, 14, and 16 to eliminate multiple dependencies, claim 12 to include inhibiting, and claim 9 to include azacitidine. Accordingly, upon entry, claims 1-12, and 14-21 are pending and under examination.